Non-Disappearing COVID Creates Another Chapter For The Pharmaceutical Industry
Portfolio Pulse from Upwallstreet
UK regulators have approved an updated COVID-19 vaccine by Pfizer and BioNTech that targets the Omicron XBB.1.5 subvariant. Moderna and Novavax have also created versions of their shots that target this variant. The U.S. plans to deploy all three vaccines in the fall season. Pfizer's updated vaccine elicited a strong antibody response in a preclinical study in mice with the highly mutated BA.2.86 subvariant of the coronavirus. Moderna's updated vaccine is expected to be effective against the BA.2.86 subvariant and is expected to be available by early October.
September 06, 2023 | 8:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioNTech's updated COVID-19 vaccine, developed in partnership with Pfizer, has been approved by UK regulators.
The approval of BioNTech's updated vaccine by UK regulators could potentially boost its stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Moderna's updated COVID-19 vaccine is expected to be effective against the BA.2.86 subvariant and is expected to be available by early October.
The promising data from Moderna's updated vaccine and its expected availability by October could potentially boost its stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Novavax has created a version of its shot that targets the Omicron XBB.1.5 subvariant.
The creation of a new version of Novavax's vaccine that targets the Omicron XBB.1.5 subvariant could potentially boost its stock in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer's updated COVID-19 vaccine has been approved by UK regulators and has shown a strong antibody response to the BA.2.86 subvariant in preclinical studies.
The approval of Pfizer's updated vaccine by UK regulators and its strong response to the BA.2.86 subvariant in preclinical studies could potentially boost its stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100